PARP Inhibitors in Ovarian Cancer: A Review David M. O’MalleyThomas C. KrivakKathleen N. Moore Review Article Open access 03 June 2023 Pages: 471 - 503
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study Chao-Hua ChiuMeng-Chih LinJin-Yuan Shih Original Research Article Open access 17 June 2023 Pages: 505 - 515
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors Todd M. BauerKathleen N. MooreSiqing Fu Original Research Article Open access 06 June 2023 Pages: 517 - 530
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA David ElseaDominic MustonMatthew Monberg Original Research Article 26 May 2023 Pages: 531 - 541
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer Angela DeMicheleNicholas RobertLynn McRoy Original Research Article Open access 10 July 2023 Pages: 543 - 558
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study Matteo SantoniFrancesco MassariCamillo Porta Original Research Article 27 June 2023 Pages: 559 - 570
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study Michelle WangShadera SlatterVivek A. Rudrapatna Original Research Article Open access 21 June 2023 Pages: 571 - 583
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study Hélène BabeyPhilippe JammeRenaud Descourt Original Research Article 13 June 2023 Pages: 585 - 591
Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis Jonathan HeseltineJennifer AllisonShien Chow Original Research Article 07 June 2023 Pages: 593 - 599
Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case–Control Study Erica M. StormDimitrios MakrakisAli Raza Khaki Original Research Article 26 June 2023 Pages: 601 - 610
Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours Chih-Chieh YenYu-Min YehChia-Jui Yen Original Research Article Open access 22 June 2023 Pages: 611 - 623
Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Nan ZhengYimin ZhangLi Li Original Research Article 23 June 2023 Pages: 625 - 636
Correction to: Relugolix: A Review in Advanced Prostate Cancer Matt Shirley Correction Open access 18 May 2023 Pages: 637 - 637
